Screener
Beam Therapeutics BEAM Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of non-controlling equity investments | 16 | (2,081) |
| Change in fair value of contingent consideration liabilities | 514 | (27) |
| Interest and other income (expense), net | 9,867 | 9,864 |
| Total other income (expense) | 12,897 | 10,956 |
| Net loss | $(94,318) | $(108,330) |
| Unrealized gain (loss) on marketable securities | (2,181) | (519) |
| Comprehensive loss | $(96,499) | $(108,849) |
| Net loss per common share, basic and diluted | $(0.91) | $(1.23) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's other income (expense)?
- Beam Therapeutics (BEAM) reported other income (expense) of $12.9M in Q1 2026.
- How has Beam Therapeutics's other income (expense) changed year-over-year?
- Beam Therapeutics's other income (expense) increased by 17.7% year-over-year, from $10.96M to $12.9M.
- What is the long-term trend for Beam Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Beam Therapeutics's other income (expense) has grown at a 90.7% compound annual growth rate (CAGR), from $23.05M to $304.64M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Beam Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude